In the BioHarmony Drug Report Database

"Preview" Icon

Treprostinil

Remodulin, Tyvaso, Trepulmix (treprostinil) is a small molecule pharmaceutical. Treprostinil was first approved as Remodulin on 2002-05-21. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. The pharmaceutical is active against prostacyclin receptor. In addition, it is known to target prostaglandin E2 receptor EP4 subtype, prostaglandin D2 receptor, prostaglandin E2 receptor EP1 subtype, prostaglandin E2 receptor EP2 subtype, and prostaglandin E2 receptor EP3 subtype. Remodulin’s patents are valid until 2029-03-29 (FDA).

 

Trade Name

 

Trepulmix
 

Common Name

 

treprostinil
 

ChEMBL ID

 

CHEMBL1237119
 

Indication

 

pulmonary hypertension
 

Drug Class

 

Prostaglandins

Image (chem structure or protein)

Treprostinil structure rendering